Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 19 2024
0mins
Source: NASDAQ.COM
- FDA Advisory Committee Recommendation: The FDA's PCNS Advisory Committee voted unanimously to recommend the approval of Eli Lilly's Alzheimer's drug, donanemab, citing substantial evidence of efficacy and disease progression slowdown.
- Alzheimer's Drug Approvals: Biogen's Leqembi was approved in the U.S. last year for early Alzheimer's disease, while Aduhelm faced discontinuation due to low sales. Prothena, AC Immune, and Cassava Sciences are also developing Alzheimer's therapies.
- Market Outlook: The global Alzheimer's Disease Therapeutics Market is projected to exceed $30.8 billion by 2033 with a CAGR of 18.8%, led by North America. Asia-Pacific is expected to see significant growth.
- Investment Opportunities: Investors interested in Alzheimer's drug approvals can consider Lilly stock or ETFs like iShares U.S. Pharmaceuticals ETF, Roundhill GLP-1 & Weight Loss ETF, Horizon Kinetics Medical ETF, and Amplify Weight Loss Drug & Treatment ETF.
- Risks and Warnings: Donanemab and Leqembi carry warnings for amyloid-related imaging abnormalities (ARIA), and the FDA has not set a decision date for donanemab following the advisory meeting delay.
Analyst Views on IHE
Wall Street analysts forecast IHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IHE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 87.580
Low
Averages
High
Current: 87.580
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
